ClinVar Miner

Submissions for variant NM_177924.5(ASAH1):c.92G>T (p.Cys31Phe)

dbSNP: rs1588999402
Minimum review status: Collection method:
Minimum conflict level:
ClinVar version:
Total submissions: 1
Download table as spreadsheet
Submitter RCV SCV Clinical significance Condition Last evaluated Review status Method Comment
Medical Affairs, Dicerna Pharmaceuticals RCV001003319 SCV001161403 likely pathogenic Farber lipogranulomatosis 2019-06-18 criteria provided, single submitter literature only Variant c.92G>T has been classified as likely pathogenic using the following rationale. Variant c.92G>T has been associated with 2 Farber disease patients from unrelated families published in separate scientific journal articles. In Saygi et al., 2015, doi.org/10.1016/S1090-3798(15)30391-3, a patient was diagnosed with severe Farber disease symptoms characteristic of Type 1 Farber disease described in Gene Reviews (https://www.ncbi.nlm.nih.gov/books/NBK488189/). The patient was homozygous for c.92G>T variants in the ASAH1 gene. A second juvenile patient in Cozma et al., 2018, DOI:10.1038/s41598-017-06604-2 was diagnosed with Farber disease characteristic of Type II-III Farber disease. The patient was homozygous for c.92G>T variants in the ASAH1 gene. Additional ceramide biomarker testing was completed in this patient along with 9 additional Farber disease patients and 2 SMA-PME patients demonstrating that C26:0 levels were significantly higher in Farber patients and SMA-PME patients compared to controls.

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. Neither the University of Utah nor the National Institutes of Health independently verfies the submitted information. If you have questions about the information contained on this website, please see a health care professional.